Endpoints 4Feb2022 Article "Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  8959 of 10557  at  2/5/2022 10:53:53 AM  by

grafzeppelin


 In response to msg 8954 by  JBWIN
view thread
Strong Buy

Re: Endpoints 4Feb2022 Article "Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity"

 why i am still here fwiw - hopefully a lot!


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
8960 Re: Endpoints 4Feb2022 Article "Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity" Biotech2050 2 2/5/2022 11:19:06 AM
8963 Re: Endpoints 4Feb2022 Article "Bristol Myers' Caforio: CELMoDs have potential to replace Revlimid and Pomalyst as blockbusters start to lose exclusivity" JBWIN 9 2/5/2022 6:43:48 PM




Financial Market Data provided by
.
Loading...